No complement receptor 1 stumps on podocytes in human glomerulopathies.

Area of Science:

• Nephrology
• Immunology
• Cell Biology

Background:

• Type one complement receptor (CR1) is the sole physiological complement inhibitor on podocytes.
• CR1 deficiency is observed in various glomerulopathies, notably lupus nephritis.
• Proteolytic cleavage of CR1 from podocyte membranes has been hypothesized as the cause of loss.

Purpose of the Study:

• To investigate if CR1 proteolytic cleavage on podocytes is a widespread phenomenon across different glomerulopathies.
• To determine the mechanism behind CR1 loss in podocytes.

Main Methods:

• Utilized monoclonal and polyclonal antibodies targeting extracellular and intracellular CR1 epitopes, respectively.
• Applied antibodies to sequential serial sections of renal biopsies from patients with various glomerulopathies.
• Analyzed CR1 expression patterns in normal and diseased glomeruli.

Main Results:

• Normal glomeruli showed consistent CR1 expression with both antibodies.
• Reduced expression of both extracellular and intracellular CR1 portions was observed in lupus nephritis, FSGS, IgA nephritis, membranous glomerulonephritis, and minimal change disease.
• A strong correlation (rs = 0.951, P < 0.001) was found between the decreased expression of extracellular and intracellular CR1 portions, confirmed in focal glomerular lesions.

Conclusions:

• Podocytes do not exhibit CR1 stumps, refuting the proteolytic cleavage hypothesis.
• CR1 loss in podocytes is attributed to diminished synthesis rather than consumption.
• Reduced CR1 synthesis may heighten podocyte vulnerability to complement-mediated injury.